Abstract:Introduction: Using the Plectin1-targeting self-assembled peptide nanoparticle (PTNP) encapsulated with BET inhibitor JQ1 and PARP inhibitor Olaparib (Ola) to target accurately and suppress non-BRCA mutant pancreatic ductal adenocarcinoma (PDAC) synergistically Method: The morphologies of self-assembled peptide nanoparticle and drug-loaded nanoparticle were assessed by transmission electron microscopy (TEM); the entrapment efficiency of nanoparticles was analyzed by high performance liquid chromatography (HPLC); the drug release profiles of drug-loaded nanoparticle in vitro was evaluated by dialysis method; the targeting ability of nanoparticles was measured by flow cytometry and laser confocal microscopy; the synergetic effect was measured by western blot and flow cytometry. The in vivo stability and tumor targeting capability of peptide nanoparticle were determined by in vivo imaging system. The in vivo therapeutic effect was verified by orthotopic PDAC model. Result: The Plectin1-targeting self-assembled peptide could rapidly self-assemble into spherical nanoparticles. The diameter of PTNP was about 20 nm, and it turned to 50 nm after drug loading. After incubation for 48 hours in 10% serum solution, the morphology of drug-loaded nanoparticles PTNP-JQ1-Ola showed no obviously change, indicating that its structure was relatively stable. The entrapment efficiencies of JQ1 and Ola were both about 70%. The results of flow cytometry and laser confocal microscopy manifested that PTNP targeted Plectin1-overexpressed PDAC cells effectively. The western blot analysis indicated that PTNP loading JQ1 combined with Ola synergistically induced DNA damage and this nano-drug system resulted in higher apoptosis rate. The result of in vivo imaging system showed that PTNP had stronger accumulation in tumor site indicating the positive targeting effect of the nanoparticles on plectin1-overexpressed tumor. The PTNP-JQ1-Ola system had stronger inhibition on PDAC growth in orthotopic model. Conclusion: The plectin1-targeting self-assembled peptide nanoparticle loading with JQ1 and Ola targets PDAC effectively and thus improving the synthetic lethality capacity on non-BRCA mutant PDAC.

A nanoplatform based on allylthiopurine bio-MOF and glycosylated AIE PARP inhibitor for cancer synthetic lethal therapy

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

A supramolecular nano-delivery system based on AIE PARP inhibitor prodrug and glycosylated pillar[5]arene for drug-resistance therapy

Enzymatic interlocking aptamer-micelles for enhanced cellular internalization and nucleus-targeted cancer phototherapy

Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer.

In Situ Formation of Fibronectin‐Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy

Multifunctional Biodegradable Nanoplatform Based on Oxaliplatin Prodrug Cross-Linked Mesoporous Polydopamine for Enhancing Cancer Synergetic Therapy

Synthetic Lethality in non-BRCA Mutant PDAC with Codelivery JQ1 and Olaparib via a Plectin1 Targeting Peptide Nanoparticle

Polyphenol-mediated biomimetic MOFs hybrid nanoplatform for catalytic cascades-enhanced cancer targeted combination therapy

All-in-One Molecular Aggregation-Induced Emission Theranostics: Fluorescence Image Guided and Mitochondria Targeted Chemo- and Photodynamic Cancer Cell Ablation

DNA Aptamer-Empowered Self-Assembly Full-Api Nanodrug for Enhanced Photodynamic and Chemotherapy Synergistic Cancer Therapy

Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin

An engineered nanoplatform inhibiting energy metabolism and lysosomal activity of tumor cells to multiply cisplatin-based chemotherapy

Polyamino acid calcified nanohybrids induce immunogenic cell death for augmented chemotherapy and chemo-photodynamic synergistic therapy

Black Phosphorus Quantum Dot Loaded Bioinspired Nanoplatform Synergized with aPD-L1 for Multimode Cancer Immunotherapy

Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality

Functional Nucleic Acids-Engineered Bio-Barcode Nanoplatforms for Targeted Synergistic Therapy of Multidrug-Resistant Cancer

Facile one-step synthesis of NIR-Responsive siRNA-Inorganic hybrid nanoplatform for imaging-guided photothermal and gene synergistic therapy

Dual chemodynamic/photothermal therapeutic nanoplatform based on DNA-functionalized prussian blue

Targeting Death Receptors for Drug-Resistant Cancer Therapy: Codelivery of Ptrail and Monensin Using Dual-Targeting and Stimuli-Responsive Self-Assembling Nanocomposites

In vivo Imaging-Guided Nanoplatform for Tumor Targeting Delivery and Combined Chemo-, Gene- and Photothermal Therapy.